Top Medical News
Transvaginal photobiomodulation helps resolve pelvic pain, dysuria
10 hours ago
Most women with interstitial cystitis/bladder pain syndrome (IC/BPS) achieve a significant reduction in pelvic pain and dysuria following transvaginal photobiomodulation (TV-PBM), previously referred as low-level laser therapy, according to real-world data.
Original New Drug Application Approvals by US FDA (16 - 30 November 2022)
New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
MDT without ADT delays systemic therapy initiation in recurrent prostate cancer
Stephen Padilla, 21 Nov 2022
In patients with solitary metastatic recurrences of prostate cancer, metastasis-directed therapy (MDT without androgen deprivation therapy (ADT) can lead to delayed initiation of systemic therapy, according to a study.
Vasovasostomy common in men undergoing vasectomy reversal after testosterone therapy
19 Nov 2022
Among men seeking vasectomy reversal (VR) after testosterone therapy (TT), vasovasostomy (VV) appears to be a very common procedure that is likely to succeed.
Microscopic haematuria linked to chronic kidney disease
19 Nov 2022
Individuals with microscopic haematuria, especially persistent haematuria, appear to be at heightened risk of chronic kidney disease, as shown in a study.
Radiotherapy vs prostatectomy: Which is better for prostate cancer treatment?
19 Nov 2022
External beam radiation therapy with low-dose rate brachytherapy boost appears to result in worse urinary irritative/obstructive and bowel functions but better urinary incontinence function through 5 years after treatment when compared to radical prostatectomy, reports a recent study.
Needle disinfection with povidone-iodine, formalin reduces infections after prostate biopsy
18 Nov 2022
Intrarectal povidone-iodine cleansing along with formalin disinfection of the biopsy needle tip helps reduce infectious complications following transrectal prostate biopsy, a study has shown.
Special Reports
Optimizing metastatic hormone-sensitive prostate cancer treatment in advanced prostate cancer
Assoc Prof. Darren Poon, Assoc Prof. Edmund Chiong, 14 Jan 2021
Metastatic hormone-sensitive prostate cancer (mHSPC) refers to the condition whereby patients have metastatic prostate cancer and no prior hormonal therapy or androgen deprivation therapy (ADT). Typically, patients with mHSPC have been treated with ADT alone, following which, the overwhelming majority develop castration resistance over time and head towards eventual mortality. In recent years, the publication of various landmark trials has prompted dramatic changes in the mHSPC treatment landscape, and had favourably impacted overall survival (OS) in these patients. At a recent webinar, A/Prof Darren Poon, Honorary Consultant in Clinical Oncology, Hong Kong Sanatorium & Hospital, and Honorary Clinical Associate Professor, Department of Clinical Oncology, The Chinese University of Hong Kong, reviewed treatment options in mHSPC, while A/Prof Edmund Chiong, Head and Senior Consultant, Department of Urology, National University Hospital, Singapore, presented a case which was discussed by an esteemed panel of experts. This webinar was jointly organized by the Singapore Society of Oncology and the Singapore Urological Association, and supported by Astellas. 
Conference Reports
Relugolix leads to rapid, sustained profound testosterone suppression in advanced PCa
Roshini Claire Anthony, 25 Aug 2022

Use of the oral non-peptide gonadotropin-releasing hormone (GnRH) receptor antagonist relugolix led to faster and greater sustained profound testosterone suppression than leuprolide in men with advanced prostate cancer, according to results of the phase III HERO study presented at EAU 2022.

Is 5-year interval sufficient for prostate cancer screening in older men?
Roshini Claire Anthony, 18 Aug 2022

Diagnosis, progression, or death due to prostate cancer occur at approximately a decade to 15 years following an initial assessment of prostate-specific antigen (PSA) levels in older men, according to a study presented at EAU 2022.

Avelumab benefit may extend to cisplatin-unfit bladder cancer patients
Audrey Abella, 08 Aug 2022
The anti-PD-L1 antibody avelumab demonstrated clinical activity as first-line treatment for patients with metastatic or locally advanced urothelial carcinoma who were PD-L1-positive and ineligible for cisplatin, according to findings from the ARIES trial presented at EAU 2022.
Abiraterone-olaparib confers clinical benefit for mCRPC patients
Audrey Abella, 04 Aug 2022
The combination of abiraterone and olaparib conferred significant improvement in radiographic progression-free survival (rPFS) in the first-line treatment of metastatic castration-resistant prostate cancer (mCRPC), according to findings from the phase III PROpel trial presented at EAU 2022.
Patients prefer being awake but sedated during urologic procedures
Elvira Manzano, 04 Aug 2022
Patients prefer conscious sedation over general anaesthesia (GA) during urologic procedures, according to Canadian researchers who followed patients undergoing various endourologic, ureteric, urethral, or advanced cystoscopic procedures.
Which drugs raise risk of urinary tract infections?
Stephen Padilla, 29 Jul 2022
Some medications may directly cause the occurrence of urinary tract infections (UTIs), and a recent study presented at the 37th Annual European Association of Urology Congress (EAU 2022) has identified six drugs that appear to contribute to “significant reporting levels” for infections.
SOUNDS: Real-world use affirms efficacy, safety of sacral neuromodulator device for OAB
Jairia Dela Cruz, 28 Jul 2022
Delivering electric stimulation to the sacral nerves using an implantable device appears to be safe and effective in the treatment of overactive bladder (OAB) in a real-world setting, according to the France-based SOUNDS study presented at the 37th Annual European Association of Urology Congress (EAU 2022).